Neumentum

Neumentum is a private, pre-revenue biotech focused on transforming pain treatment through a pipeline of non-opioid analgesics. Its lead assets include NTM-001, a late-stage, novel formulation of ketorolac for continuous infusion, and NTM-006, a novel oral compound with a new mechanism of action. The company is targeting a massive market driven by the opioid crisis and the critical need for effective, safer pain management alternatives, led by an experienced team with deep expertise in pain drug development and commercialization.

Product development platform focused on reformulating known non-opioid analgesics and developing novel chemical entities (NCEs) with new mechanisms of action for pain.

The non-opioid pain market is competitive, with numerous biotech and pharmaceutical companies exploring diverse mechanisms including NaV channel inhibitors, NGF antibodies, novel NSAID formulations, and other NCEs. Neumentum competes with firms like Vertex (NaV1.8), Regeneron (NGF antibody fasinumab), and others, as well as generic non-opioid options.